Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465099 · ClinicalTrials.gov registry record · Phase 4
Posterior Spinal Fusion With Two Energy Dissection Techniques
A Phase 4 study, sponsored by Ethicon Endo-Surgery.
- Terminated
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT02465099: Clinical Trial Phase 4 study, sponsored by Ethicon Endo-Surgery.
NCT02465099 is a Phase 4 study that was terminated before completion, run by Ethicon Endo-Surgery. The registered enrollment target is 64 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02465099, a Phase 4 study, was terminated before completion, sponsored by Ethicon Endo-Surgery.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
The OSTEOVUE™ Spine Dissector is a new ultrasonic energy device, specifically designed for soft tissue removal from vertebral surfaces. The aim of the present study is to compare blood loss in multilevel PSF surgeries in patients with adolescent scoliosis (idiopathic or neuromuscular) done with ED or with UD. Blood loss will be estimated by major intraoperative surgical Stage (1 and 2) and postoperatively (until discharge). Additionally, the study will assess the possible influence of the device use in secondary perioperative outcomes.
Primary Outcome
Estimated blood loss during intraoperative Stage 1, defined as the period from first incision to the first bone violation/cut (e.g., first pedicle screw drill); and intraoperative Stage 2, defined as the period from first bone violation/cut to last suture.
Interventions
- DEVICE Ultrasonic Dissection (UD)
- DEVICE Electrocautery Dissection (ED)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-06-01 |
| Est. Completion | 2016-05-01 |
| Phase | Phase 4 |
Why NCT02465099 stopped before completion
NCT02465099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Ultrasonic Dissection (UD) is the first listed.
NCT02465099 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02465099 about?
NCT02465099 is a clinical study titled "Posterior Spinal Fusion With Two Energy Dissection Techniques". The OSTEOVUE™ Spine Dissector is a new ultrasonic energy device, specifically designed for soft tissue removal from vertebral surfaces. The aim of the present study is to compare blood loss in multilevel PSF surgeries in patients with adolescent scoliosis (idiopathic or neuromuscular) done with ED o...
What is the current status of trial NCT02465099?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2015-06-01. Estimated completion is 2016-05-01.
What interventions are being tested in trial NCT02465099?
The interventions under investigation include: Ultrasonic Dissection (UD) (DEVICE), Electrocautery Dissection (ED) (DEVICE).
Who is sponsoring clinical trial NCT02465099?
This trial is sponsored by Ethicon Endo-Surgery, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02465099's enrollment target sits among peer trials
64 1098th of 2000 higher than 895 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI